A Study to Assess the Efficacy and Safety of Nusinersen (ISIS 396443) in Infants With Spinal Muscular Atrophy

Stopped early · Phase 3 · Has a placebo group

Conditions studied: Spinal Muscular Atrophy

In brief

The primary objective of the study is to examine the clinical efficacy of nusinersen (ISIS 396443) administered intrathecally (IT) to participants with infantile-onset with infantile-onset spinal muscular atrophy (SMA). The secondary objective of the study is to examine the safety and tolerability of nusinersen administered intrathecally to participants with infantile-onset SMA.

Key facts

Study ID
NCT02193074
Run by
Biogen
People needed
122
Starts
2014-08-19
Expected to finish
2016-11-21
Last updated by the study team
2021-02-17

Who can join

Age: any, up to 1. Sex: any. Healthy volunteers: not accepted.

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.